Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells

Table 1 Correlation of galectin-1 with the histopathological parameters of HCC patients

Histopathological parameters	T/NT < 2 (without Gal-1 overexpression)	T/NT ≥ 2 (with Gal-1 overexpression)	P-value
Sex
Male	47	23	0.794
Female	13	8	0.794
Cirrhotic liver
Cirrhosis	18	6	0.402
NT & hepatitis	22	14	0.402
HBsAg
Positive	38	16	0.712
Negative	6	4	0.712
Cellular differentiation
Poor	22	8	0.130
Differentiated	18	12	0.130
Tumor size
> 5 cm	26	15	0.560
≤ 5 cm	14	5	0.560
Tumor encapsulation
Absent	21	16	0.008*
Present	27	4	0.008*
Venous invasion
Present	27	19	0.270
Absent	29	12	0.270
Microsatellite
Present	17	15	0.032*
Absent	25	6	0.032*
Direct liver invasion
Present	11	7	0.551
Absent	23	10	0.551
Tumor nodule
N ≥ 2	10	7	0.547
N = 1	29	13	0.547

T Tumorous, NT non-tumorous, N number of tumor nodule, HBsAg Hepatitis B surface antigen, P < 0.05 is regarded as statistically significant
*P < 0.05 is regarded as statistically significant

ISSN: 1756-9966